RJ Hamster
Celebrate everyone’s unique identity and passions with custom t-shirts, stickers, posters, coffee mugs and more. Everyone is welcome.
— Read on www.cafepress.com/
RJ Hamster
You’ve likely heard about Netflix’s offer to buy Warner Bros.
But while the mainstream financial media focuses on that major story…
Joel Litman and Rob Spivey of our corporate affiliate, Altimetry, are focused on a series of much smaller acquisitions we haven’t seen anyone in the media comment on.
In short: Joel and Rob believe that when these new deals are announced – one of which could happen as early as TOMORROW – they could each double your money in 24 hours or less.
But you’re running out of time to make your move on this urgent opportunity.
Before midnight tonight, click here for the full story.
Regards,
Matthew Weinschenk
Director of Research, Stansberry Research
P.S. Here’s Rob with more, including details on the special invitation they’re extending to Stansberry Research readers until midnight tonight…
———- Forwarded message ———
Dear Reader,
Until midnight tonight, Joel and I are offering you essentially seven FREE months of our research in Microcap Confidential…
Along with an entire FREE year of access to the highest level of our forensic accounting tool, the Altimeter Pro…
As part of a special offer in honor of our newest One-Day Double stock recommendations.
In other words, you’re running out of time to get started, and we’ll need to hear from you today.
Now, the reason we stepped forward this week is simple:
Joel and I have found a tiny stock (which many of the world’s top investors recently opened a position in) that we believe could DOUBLE YOUR MONEY in a single day…
Before the end of this month…
Along with a shortlist of stocks that could do the exact same in the early part of 2026.
We identified these stocks (names you’ve likely never heard of before) by using the same forensic accounting approach we’ve used in the past five years to spot nearly two dozen other stocks that saw big one-day gains, including one that shot up 120% in a single day.
In short, we’ve picked up on a MASSIVE distortion between these companies’ TRUE earnings and those reported to the public using Generally Accepted Accounting Principles (GAAP).
And because of these firms’ small size, we believe this discrepancy makes them extremely attractive acquisition targets to much larger competitors.
Which is why it’s so important to get started with our newest One-Day Double recommendations – IMMEDIATELY.
We are extremely confident that these acquisitions are imminent.
Thanks to a massive convergence of catalysts – political, economic, and calendar – which Joel and I outlined in Monday’s briefing…
We believe we’re looking at the most obvious setup we’ve seen all year for the biggest, fastest gain possible.
As of right now… these deals have not yet been announced.
But the instant this story breaks, we expect the stocks to soar on the news… giving you the chance to double your money – at least – in less than 24 hours.
However, if you’re still sitting on the sidelines… You will almost certainly miss out on the opportunity for these big, fast gains entirely.
That’s why the most important thing you can do is get the names of our newest One-Day Double stock recommendations.
Remember, once a potential deal is announced, your chance for these gains will be gone.
Click here for the full details before midnight tonight.
Regards,
Rob Spivey
Director of Research, Altimetry
P.S. Don’t forget, since we got started with this forensic accounting approach in 2009… we’ve used it to find dozens of big winners – simply by looking in places most other investors wouldn’t ever think of looking.
Here’s a tiny snapshot of some of the real gains our institutional clients could have seen by following our recommendations:
While these gains were impressive, we believe our newest One-Day Double recommendations could result in our biggest, fastest gains yet.
So don’t delay…
Click here to get the name of these tiny stocks before midnight tonight.
Published by Stansberry Research.
You have received this e-mail as part of your optin to Stansberry Research. If you no longer wish to receive special offers from Stansberry Research, click here.
You’re receiving this e-mail at pahovis@aol.com. Stansberry Research welcomes comments or suggestions at feedback@stansberryresearch.com . This address is for feedback only. For questions about your account or to speak with customer service, call 888-261-2693 (U.S.) or 443-839-0986 (international) Monday-Friday, 9 a.m.-5 p.m. Eastern time. Or e-mail info@stansberryresearch.com. Please note: The law prohibits us from giving personalized financial advice.
© 2025 Stansberry Research. All rights reserved. Any reproduction, copying, or redistribution, in whole or in part, is prohibited without written permission from Stansberry Research, 1125 N Charles St, Baltimore, MD 21201stansberryresearch.com.
RJ Hamster
Holiday – SkincareEssentials
— Read on skincareessentials.com/pages/holiday
RJ Hamster
 Stay informed and inspired!Download Flipboard to get the latest news and stories on the topics you care about.Get the App |
Was this sent to you by a friend? For more like it, subscribe here.BLOG · CAREERS · ADVERTISE Update your email preferences or unsubscribe here.View our privacy policy here.©2025 Flipboard, Inc. Made with love at 555 Bryant St #352 Palo Alto, CA 94301 |
RJ Hamster
Sponsored content from SmallCaps Daily
NNVC Looks Poised for Transformative Growth as Zacks Highlights NV-387’s Broad-Spectrum Antiviral Potential Across Biodefense and Global Viral Threats. Zacks Has Issued a $7 Valuation!
NanoViricides (NYSE: NNVC) is capturing investor attention as the company’s leading drug candidate NV-387 prepares to enter Phase 2 clinical trials for MPox, a strategic step toward addressing both emerging viral threats and biodefense needs.
NV-387’s novel nanoviricide technology not only neutralizes viruses before infection but also protects critical organs like the lungs, offering a unique therapeutic advantageover conventional antivirals.
Dual-track clinical plans, including basket-type trials for respiratory viruses, position NNVC to expand NV-387’s utility across measles, influenza, RSV, and coronaviruses — a potential multi-billion-dollar antiviral m arket.
With a $7 valuation, Zacks Small Cap Research underscores NNVC’s promising outlook, emphasizing NV-387’s potential for strategic government procurement, orphan drug exclusivity, and BARDA funding.
NNVC’s Phase 1 safety data, broad preclinical efficacy, and advanced clinical planning suggest an asymmetric upside for investors. With trials imminent and a clear path to regulatory milestones, NNVC stands ready to redefine antiviral therapy.
Positive results from the company’s Phase 2 clinical trials for MPox could have immediate implications for FDA approval under the Animal Rule for Smallpox, unlocking a $1 billion market via the U.S. Strategic National Stockpile and potential BARDA funding — a major milestone for shareholder value!
See how NNVC is gearing up to transform the antiviral landscape while catching Wall Street attention
Thank you for subscribing to DividendStocks.com’s daily newsletter for dividend and income investors that covers ex-dividend stocks, new dividend declarations, dividend stock ideas, and the latest market news.
This email message is a sponsored email sent on behalf of SmallCaps Daily, a third-party advertiser of DividendStocks.comand MarketBeat.
This message is a paid advertisement for NanoViricides, Inc. (NYSE American: NNVC) from SmallCaps Daily and Interactive Offers. MarketBeat Media, LLC receives a fixed fee for each subscriber that clicks on a link in this email, totaling up to $10,000. Other than the compensation received for this advertisement sent to subscribers, MarketBeat and its principals are not affiliated with either SmallCaps Daily or Interactive Offers. MarketBeat and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither MarketBeat nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from MarketBeat to buy or sell any security. MarketBeat has not evaluated the accuracy of any claims made in this advertisement. MarketBeat recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding NanoViricides, Inc. (NYSE American: NNVC) on Interactive Offers’ website for additional information about the relationship between Interactive Offers and NanoViricides, Inc. (NYSE American: NNVC).
If you need help with your newsletter, please don’t hesitate to contact our U.S. based support team at contact@marketbeat.com.
If you no longer wish to receive email from DividendStocks.com, you can unsubscribe.
© 2006-2025 MarketBeat Media, LLC. All rights reserved.
345 North Reid Place, Suite 620, Sioux Falls, South Dakota 57103-7078. United States of America..
Read More: 5 Stocks with Rare Profit Window? (Click to Opt-In)
Sponsored content from SmallCaps Daily
NNVC Looks Poised for Transformative Growth as Zacks Highlights NV-387’s Broad-Spectrum Antiviral Potential Across Biodefense and Global Viral Threats. Zacks Has Issued a $7 Valuation!
NanoViricides (NYSE: NNVC) is capturing investor attention as the company’s leading drug candidate NV-387 prepares to enter Phase 2 clinical trials for MPox, a strategic step toward addressing both emerging viral threats and biodefense needs.
NV-387’s novel nanoviricide technology not only neutralizes viruses before infection but also protects critical organs like the lungs, offering a unique therapeutic advantageover conventional antivirals.
Dual-track clinical plans, including basket-type trials for respiratory viruses, position NNVC to expand NV-387’s utility across measles, influenza, RSV, and coronaviruses — a potential multi-billion-dollar antiviral m arket.
With a $7 valuation, Zacks Small Cap Research underscores NNVC’s promising outlook, emphasizing NV-387’s potential for strategic government procurement, orphan drug exclusivity, and BARDA funding.
NNVC’s Phase 1 safety data, broad preclinical efficacy, and advanced clinical planning suggest an asymmetric upside for investors. With trials imminent and a clear path to regulatory milestones, NNVC stands ready to redefine antiviral therapy.
Positive results from the company’s Phase 2 clinical trials for MPox could have immediate implications for FDA approval under the Animal Rule for Smallpox, unlocking a $1 billion market via the U.S. Strategic National Stockpile and potential BARDA funding — a major milestone for shareholder value!
See how NNVC is gearing up to transform the antiviral landscape while catching Wall Street attention
Thank you for subscribing to DividendStocks.com’s daily newsletter for dividend and income investors that covers ex-dividend stocks, new dividend declarations, dividend stock ideas, and the latest market news.
This email message is a sponsored email sent on behalf of SmallCaps Daily, a third-party advertiser of DividendStocks.comand MarketBeat.
This message is a paid advertisement for NanoViricides, Inc. (NYSE American: NNVC) from SmallCaps Daily and Interactive Offers. MarketBeat Media, LLC receives a fixed fee for each subscriber that clicks on a link in this email, totaling up to $10,000. Other than the compensation received for this advertisement sent to subscribers, MarketBeat and its principals are not affiliated with either SmallCaps Daily or Interactive Offers. MarketBeat and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither MarketBeat nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from MarketBeat to buy or sell any security. MarketBeat has not evaluated the accuracy of any claims made in this advertisement. MarketBeat recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding NanoViricides, Inc. (NYSE American: NNVC) on Interactive Offers’ website for additional information about the relationship between Interactive Offers and NanoViricides, Inc. (NYSE American: NNVC).
If you need help with your newsletter, please don’t hesitate to contact our U.S. based support team at contact@marketbeat.com.
If you no longer wish to receive email from DividendStocks.com, you can unsubscribe.
© 2006-2025 MarketBeat Media, LLC. All rights reserved.
345 North Reid Place, Suite 620, Sioux Falls, South Dakota 57103-7078. United States of America..
Read More: 5 Stocks with Rare Profit Window? (Click to Opt-In)
Sponsored content from SmallCaps Daily
NNVC Looks Poised for Transformative Growth as Zacks Highlights NV-387’s Broad-Spectrum Antiviral Potential Across Biodefense and Global Viral Threats. Zacks Has Issued a $7 Valuation!
NanoViricides (NYSE: NNVC) is capturing investor attention as the company’s leading drug candidate NV-387 prepares to enter Phase 2 clinical trials for MPox, a strategic step toward addressing both emerging viral threats and biodefense needs.
NV-387’s novel nanoviricide technology not only neutralizes viruses before infection but also protects critical organs like the lungs, offering a unique therapeutic advantageover conventional antivirals.
Dual-track clinical plans, including basket-type trials for respiratory viruses, position NNVC to expand NV-387’s utility across measles, influenza, RSV, and coronaviruses — a potential multi-billion-dollar antiviral m arket.
With a $7 valuation, Zacks Small Cap Research underscores NNVC’s promising outlook, emphasizing NV-387’s potential for strategic government procurement, orphan drug exclusivity, and BARDA funding.
NNVC’s Phase 1 safety data, broad preclinical efficacy, and advanced clinical planning suggest an asymmetric upside for investors. With trials imminent and a clear path to regulatory milestones, NNVC stands ready to redefine antiviral therapy.
Positive results from the company’s Phase 2 clinical trials for MPox could have immediate implications for FDA approval under the Animal Rule for Smallpox, unlocking a $1 billion market via the U.S. Strategic National Stockpile and potential BARDA funding — a major milestone for shareholder value!
See how NNVC is gearing up to transform the antiviral landscape while catching Wall Street attention
Thank you for subscribing to DividendStocks.com’s daily newsletter for dividend and income investors that covers ex-dividend stocks, new dividend declarations, dividend stock ideas, and the latest market news.
This email message is a sponsored email sent on behalf of SmallCaps Daily, a third-party advertiser of DividendStocks.comand MarketBeat.
This message is a paid advertisement for NanoViricides, Inc. (NYSE American: NNVC) from SmallCaps Daily and Interactive Offers. MarketBeat Media, LLC receives a fixed fee for each subscriber that clicks on a link in this email, totaling up to $10,000. Other than the compensation received for this advertisement sent to subscribers, MarketBeat and its principals are not affiliated with either SmallCaps Daily or Interactive Offers. MarketBeat and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither MarketBeat nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from MarketBeat to buy or sell any security. MarketBeat has not evaluated the accuracy of any claims made in this advertisement. MarketBeat recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding NanoViricides, Inc. (NYSE American: NNVC) on Interactive Offers’ website for additional information about the relationship between Interactive Offers and NanoViricides, Inc. (NYSE American: NNVC).
If you need help with your newsletter, please don’t hesitate to contact our U.S. based support team at contact@marketbeat.com.
If you no longer wish to receive email from DividendStocks.com, you can unsubscribe.
© 2006-2025 MarketBeat Media, LLC. All rights reserved.
345 North Reid Place, Suite 620, Sioux Falls, South Dakota 57103-7078. United States of America..
Read More: 5 Stocks with Rare Profit Window? (Click to Opt-In)
RJ Hamster
RJ Hamster
Discover irresistible recipes for every occasion—from easy weeknight dinners to decadent desserts, snacks, soups and more. Your go-to food blog for fresh ideas.
— Read on trulyrecipes.com/
RJ Hamster
Wednesday, December 10
© 2025 MLB Advanced Media, L.P. MLB trademarks and copyrights are used with permission of Major League Baseball. Visit MLB.com. Any other marks used herein are trademarks of their respective owners.
Please review our Privacy Policy.
You (peterhovis@icloud.com) received this message because you registered to receive commercial email messages from mlb.com.
Please add info@marketing.mlbemail.com to your address book to ensure our messages reach your inbox. If you no longer wish to receive commercial email messages from mlb.com, please unsubscribe or log in and manage your email subscriptions.
Postal Address: mlb.com, c/o MLB Advanced Media, L.P., 1271 Avenue of the Americas, New York, NY 10020.
RJ Hamster
Elevate your pet’s nutrition with Kahoots’ dog and cat food, offering both exceptional taste and health benefits. Our versatile, rotational diet allows for seamless transitions within product lines, preventing digestive issues and food sensitivities. With options like chicken and lamb, your pet can enjoy a variety of meals without monotony.
Our balanced formulas are suitable for all life stages, from playful puppies and kittens to senior pets. Meeting AAFCO guidelines for All Life Stages, there’s no need for separate foods for different ages or breeds.
We prioritize quality with meat-based formulas, using top ingredients like nutrient-rich French duck and pristine Norwegian salmon oil, while avoiding fillers with minimal nutritional value. Each bite is packed with essential nutrients to support your pet’s health.
Kahoots offers options for every pet, including both grain-inclusive and grain-free, as well as canned and dry food. No matter your pet’s preference, you’ll find a delicious and nutritious choice with us. Shop Dog FoodShop Cat Food
No longer want to receive these emails? Unsubscribe
Kahoots Pet | PO Box 2123 Ramona CA 92065
RJ Hamster
Need help? Call us: 888.492.7297, every day, 8 a.m.–11 p.m. ET, or visit our FAQ page. Find a Warby Parker store near you Learn about Buy a Pair, Give a Pair You’re receiving this email because you agreed to receive emails from Warby Parker. To stop marketing emails, update your preferences in your Warby Parker account settings (if you have an account) or click “unsubscribe” below. 233 Spring Street, 6th Floor East, New York City, NY 10013 View in browser | Privacy | Terms of Use | Unsubscribe